[{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Cinrebafusp Alpha","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ University of Sydney"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Merger","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Caladrius Biosciences"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IM156","moa":"||AMP-activated protein kinase (AMPK)","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoMet \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMet \/ Undisclosed"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Eoc Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Eoc Pharma"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ European Investment Bank"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Toray Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||CAPRIN1","graph1":"Oncology","graph2":"Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bolt Biotherapeutics \/ Toray Industries","highestDevelopmentStatusID":"8","companyTruncated":"Bolt Biotherapeutics \/ Toray Industries"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PEP-Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Undisclosed"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PEP-Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Oncolytics Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Adlai Nortye","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Adlai Nortye"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Kitov Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Purple Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Purple Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sotio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Connective tissue growth factor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Connective tissue growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Connective tissue growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"||Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Dickkopf-related protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DLL4\/VEGF-A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DLL4\/VEGF-A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Paclitaxel","moa":"||DLL4\/VEGF-A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"||DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Golden Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Surface Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Deka Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series B Financing","leadProduct":"Carboplatin","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Deka Biosciences \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ MPM BioImpact"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Deka Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||enzyme inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Funding","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ EIC Accelerator"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||ergot alkaloid derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Humanetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"||Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NGM120","moa":"||GDNF family receptor alpha-like (GFRAL)","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"||GDNF family receptor alpha-like (GFRAL)","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"||GDNF family receptor alpha-like (GFRAL)","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NGM120","moa":"||GDNF family receptor alpha-like (GFRAL)","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor messenger RNA (GCR mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ORIC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IPN60090","moa":"||Glutaminase-1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||Glycogen synthase kinase-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||Glycogen synthase kinase-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||Glycogen synthase kinase-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||Glycogen synthase kinase-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actuate Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aravive \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Aravive","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Aravive \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ BVF Partners"},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aravive \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Aravive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"||Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase I","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aveo Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aveo Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"||Inhibitor of apoptosis protein (hIAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Imunon \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Undisclosed"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Financing","leadProduct":"Carboplatin","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Imunon \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arch Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"AO-176","moa":"||Leukocyte surface antigen CD47 (CD47)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Arch Oncology \/ Eventide Asset Management","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Eventide Asset Management"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ National Cancer Institute"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Atebimetinib","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immunering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunering","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunering \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunering \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase III","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncXerna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OncXerna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OncXerna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Hepalink Pharmaceutical","sponsor":"Orient EuroPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Hepalink Pharmaceutical","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CanariaBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Undisclosed"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanariaBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Undisclosed"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hikma Pharmaceuticals \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ CanariaBio"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Dual Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Divestment","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0.38,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Infusion","sponsorNew":"OncoQuest \/ Dual Industrial","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Dual Industrial"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoQuest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Undisclosed"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Specialised Therapeutics \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Specialised Therapeutics \/ CanariaBio"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nab-Paclitaxel","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"||PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"||PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buparlisib","moa":"||PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Undisclosed"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Nucleai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Buparlisib","moa":"||PI3-kinase class I","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Nucleai","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Nucleai"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faeth Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"||PI3-kinase p110-gamma subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sun BioPharma \/ Craig-Hallum Capital Group","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Craig-Hallum Capital Group"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Tangdu Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Tangdu Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tangdu Hospital \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tangdu Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Dawnrays Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK109","moa":"||Programmed cell death protein 1 | Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Dawnrays Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Dawnrays Pharmaceutical"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Cadonilimab","moa":"||Programmed cell death protein 1 | Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Sonire therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Sonire therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonire therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sonire therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Undisclosed"},{"orgOrder":0,"company":"Novocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Undisclosed"},{"orgOrder":0,"company":"Greenfire Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GRN-300","moa":"||Salt-inducible kinase 2 (SIK2)","graph1":"Oncology","graph2":"Phase I","graph3":"Greenfire Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Greenfire Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Greenfire Bio \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Asparagine","moa":"||Sodium-coupled neutral amino acid transporters; Neutral amino acid transporter B(0); Asparagine synthetase [glutamine-hydrolyzing]; Asparagine--tRNA ligase, cytoplasmic; Isoaspartyl peptidase\/L-asparaginase; Asparaginyl-tRNA synthetase","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GFH018","moa":"||TGF-beta-1","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like receptor 3","graph1":"Oncology","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aim ImmunoTech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aim ImmunoTech \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||TOP2","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ CytRx Corporation"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||TOP2","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ CytRx Corporation"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"||Transforming growth factor beta (TGFB)","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.52000000000000002,"dosageForm":"Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Chinese Academy of Medical Sciences","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Chinese Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chinese Academy of Medical Sciences \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Chinese Academy of Medical Sciences \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"CTTQ Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ CTTQ Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sun Yat-sen University \/ CTTQ Pharma"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Innovent Biologics | CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase IV","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Innovent Biologics | CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Innovent Biologics | CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Huazhong University of Science and Technology","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Huazhong University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huazhong University of Science and Technology \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Huazhong University of Science and Technology \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Peking University","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Peking University \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Fujian Cancer Hospital","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Fujian Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Cancer Hospital \/ Suzhou Suncadia Biopharmaceuticals Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Cancer Hospital \/ Suzhou Suncadia Biopharmaceuticals Co., Ltd."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CSPC Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"THERABIONIC INC.","sponsor":"Therabionics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"THERABIONIC INC.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"THERABIONIC INC. \/ Therabionics","highestDevelopmentStatusID":"8","companyTruncated":"THERABIONIC INC. \/ Therabionics"},{"orgOrder":0,"company":"Northwestern University","sponsor":"CarThera | Bristol Myers Squibb | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northwestern University \/ CarThera | Bristol Myers Squibb | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Northwestern University \/ CarThera | Bristol Myers Squibb | National Cancer Institute"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Merck & Co"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corcept Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"NanOlogy \/ US Biotest, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ US Biotest, Inc."},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"NanOlogy \/ US Biotest, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ US Biotest, Inc."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Novocure","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ Novocure"},{"orgOrder":0,"company":"Jianjun Yang","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Jianjun Yang","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jianjun Yang \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Jianjun Yang \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Ashish Manne","sponsor":"Novocure | Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Ashish Manne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ashish Manne \/ Novocure | Ohio State University","highestDevelopmentStatusID":"8","companyTruncated":"Ashish Manne \/ Novocure | Ohio State University"},{"orgOrder":0,"company":"Novocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NovoTTF-100L","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Provincial Cancer Hospital","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Anhui Provincial Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anhui Provincial Cancer Hospital \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Anhui Provincial Cancer Hospital \/ Hutchmed"},{"orgOrder":0,"company":"Shanghai Yizhong Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yizhong Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yizhong Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Yizhong Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yizhong Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yizhong Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yizhong Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Yizhong Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Henan Cancer Hospital \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"8","companyTruncated":"Henan Cancer Hospital \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Dihua Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Dihua Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Dihua Biotechnology"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Japanese Foundation for Cancer Research","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Japanese Foundation for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Japanese Foundation for Cancer Research \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Japanese Foundation for Cancer Research \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Health Hope Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Health Hope Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Health Hope Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Health Hope Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Venus Remedies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Boryeong"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Samyang Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Samyang Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samyang Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samyang Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kexing Biopharm \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Kexing Biopharm \/ IQVIA"},{"orgOrder":0,"company":"Intergroupe Francophone de Cancerologie Thoracique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Intergroupe Francophone de Cancerologie Thoracique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed"},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Inceptua Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inceptua Group \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Inceptua Group \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Novocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Undisclosed"},{"orgOrder":0,"company":"Novocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fidia Farmaceutici Spa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fidia Farmaceutici Spa \/ Undisclosed"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Fidia Farmaceutici Spa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fidia Farmaceutici Spa \/ Undisclosed"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fidia Farmaceutici Spa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fidia Farmaceutici Spa \/ Undisclosed"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fidia Farmaceutici Spa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fidia Farmaceutici Spa \/ Undisclosed"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Merck & Co | Centre L\u00e9on B\u00e9rard","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NETRIS Pharma \/ Merck & Co | Centre L\u00e9on B\u00e9rard","highestDevelopmentStatusID":"7","companyTruncated":"NETRIS Pharma \/ Merck & Co | Centre L\u00e9on B\u00e9rard"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Canadian Cancer Trials Group \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"BW Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"BW Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BW Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BW Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Urotronic Inc.","sponsor":"Laborie Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Urology","graph2":"Phase IV","graph3":"Urotronic Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urotronic Inc. \/ Laborie Medical Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Urotronic Inc. \/ Laborie Medical Technologies"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ GSK"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Merck & Co"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Catalyst Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Catalyst Health Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Catalyst Health Ventures"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"PrECOG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ PrECOG","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ PrECOG"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Nanjing King-friend Biochemical Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meitheal Pharmaceuticals \/ Nanjing King-friend Biochemical Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Nanjing King-friend Biochemical Pharmaceutical"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ US Biotest","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ US Biotest"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Pharma \/ Fulgent Genetics"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Huons CO., LTD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Huons CO., LTD","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Huons CO., LTD"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Undisclosed"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jina Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"GIE Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"GIE Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GIE Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GIE Medical \/ Undisclosed"},{"orgOrder":0,"company":"GIE Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"GIE Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GIE Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GIE Medical \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"MacroGenics | Translational Breast Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ MacroGenics | Translational Breast Cancer Research Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ MacroGenics | Translational Breast Cancer Research Consortium"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Imunon","sponsor":"Breakthrough Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imunon \/ Breakthrough Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Breakthrough Cancer Research"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Aravive","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Aravive","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Aravive"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Athenex","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Athenex"},{"orgOrder":0,"company":"Surmodics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Abbott Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Abbott Laboratories"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanOlogy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Undisclosed"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTher Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PanTher Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Airiver Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Airiver Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Airiver Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Airiver Medical \/ Undisclosed"},{"orgOrder":0,"company":"Airiver Medical","sponsor":"Libra Medical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airiver Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Airiver Medical \/ Libra Medical","highestDevelopmentStatusID":"6","companyTruncated":"Airiver Medical \/ Libra Medical"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pyxis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"VCN Biosciences \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Grifols International"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Abraxane","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"VCN Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ VCN Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ VCN Biosciences"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Tumor Stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor Stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Tumor Stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elpiscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rebastinib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Termination","leadProduct":"Canerpaturev","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Genelux","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genelux \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Sandoz B2B"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Pharmapark"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Centus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centus Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Centus Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Eli Lilly"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"||VEGFA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||VEGFA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||VEGFA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Undisclosed"},{"orgOrder":0,"company":"Teleflex Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SINGAPORE","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Endocrinology","graph2":"Phase I","graph3":"Teleflex Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Teleflex Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teleflex Medical \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Paclitaxel

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The partnership aims to accelerate the global clinical development, regulatory approval, and commercialization of Kexing's innovative drugs and biosimilars, including Apexelsin (nab-paclitaxel).

                          Product Name : Apexelsin

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          August 11, 2025

                          Lead Product(s) : Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : IQVIA

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Zynyz (retifanlimab) is a PD-1–blocking antibody candidate, which is approved by USFDA for the treatment of fifirst-line treatment for advanced anal cancer.

                          Product Name : Zynyz

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          May 15, 2025

                          Lead Product(s) : Retifanlimab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ivonescimab, known as SMT112 in Summit’s license territories and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 23, 2025

                          Lead Product(s) : Ivonescimab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Summit Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PEP-010, is currently undergoing early-stage clinical trials in combination with paclitaxel/gemcitabine for treating advanced/metastatic ovarian cancer & metastatic pancreatic ductal adenocarcinoma.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : PEP-010,Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel, is a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism bein studied in patients with endometrial cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 12, 2025

                          Lead Product(s) : Serabelisib,Paclitaxel,Sapanisertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : GOG Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The collaboration aims to develop TRK-950, an Caprin-1 designed to target multiple solid tumor types. Currently, it is being evaluated for the treatment of gastric cancer.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          February 11, 2025

                          Lead Product(s) : TRK-950,Paclitaxel,Ramucirumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Toray Industries

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (PDAC).

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          December 05, 2024

                          Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tumor Treating Fields therapy concomitantly with gemcitabine and nab-paclitaxel is being investigated as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Keytruda (pembrolizumab) is an anti-PD-1 therapy, indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy.

                          Product Name : Keytruda

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 24, 2024

                          Lead Product(s) : Pembrolizumab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The proceeds will be used in accelerating the global clinical development of innovative drugs developed internally by Akeso, including AK-104 (cadonilimab) for first-line treatment of cervical cancer.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          October 13, 2024

                          Lead Product(s) : Cadonilimab,Cisplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : $250.0 million

                          Deal Type : Private Placement

                          blank